
RealRate

PHARMACEUTICAL 2018

MABVAX THERAPEUTICS HOLDINGS INC. Rank 326 of 349



RealRate

PHARMACEUTICAL 2018

MABVAX THERAPEUTICS HOLDINGS INC. Rank 326 of 349

The relative strengths and weaknesses of MABVAX THERAPEUTICS HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MABVAX THERAPEUTICS HOLDINGS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 430% points. The greatest weakness of MABVAX THERAPEUTICS HOLDINGS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 507% points.

The company's Economic Capital Ratio, given in the ranking table, is -924%, being 646% points below the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	1,208
Cost of Goods Sold	0
Intangible Assets	6,826
Liabilities, Current	5,806
Liabilities, Non-Current	1,854
Other Assets	179
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-950
Property and Equipment	578
Research and Development	7,544
Revenues	0
Selling, General and Administrative Expense	10,526

Output Variable	Value in 1000 USD
Assets	8,790
Liabilities	7,660
Expenses	18,070
Stockholders Equity	1,130
Net Income	-19,021
Comprehensive Net Income	-19,021
Economic Capital Ratio	-924%